50901-42-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Pyridazine-4-carbaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Dye and Fine Chemical Manufacturing:
Pyridazine-4-carbaldehyde serves as an important intermediate in the production of dyes and other fine chemicals. Its presence in these compounds contributes to their color and functional properties.
Used in Materials Science and Catalysis:
Pyridazine-4-carbaldehyde is utilized in the preparation of coordination complexes for applications in materials science and catalysis. Its ability to form stable complexes with metal ions enhances the performance of catalysts and materials in various chemical processes.
Used in Antibacterial and Antifungal Applications:
Pyridazine-4-carbaldehyde has been studied for its potential biological activities, including antibacterial and antifungal properties. Its presence in compounds can help combat infections caused by various microorganisms, making it a valuable component in the development of antimicrobial agents.

InChI:InChI=1/C5H4N2O/c8-4-5-1-2-6-7-3-5/h1-4H

Upstream product

• 77709-03-6 4-symm.Trioxanylpyridazin 
• 1120-88-3 4-methylpyridazine 
• 39816-19-8 4-styrylpyridazine 

Downstream Products

• 34231-77-1 methyl pyridazine-4-carboxylate 
• 50901-46-7 Methyl 4-pyridazinyl ketone 
• 1417700-03-8 C₂₅H₃₀N₄O₃ 
• 85226-66-0 2-(4-pyridazinyl)benzothiazole 
• 50901-50-3 pyridazine-4-carbaldehyde oxime 
• 187266-25-7 (4-Methoxy-phenyl)-[1-pyridazin-4-yl-meth-(E)-ylidene]-amine 

Relevant academic research and scientific papers

BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS

Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.

Inhibitors of protein isoprenyl transferases

Compounds having the formula STR1or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 --, and (i) heterocyclic-L 2 --; R 2 is selected from STR2(b) --C(O)NH--CH(R 14)--C(O)OR 15, STR3(d) --C(O)NH--CH(R 14)--C(O)NHSO 2 R 16, (e) --C(O)NH--CH(R 14)-tetrazolyl, (f) --C(O)NH-heterocyclic, and (g) --C(O)NH--CH(R 14)--C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) --L 4 --N(R 5)--L 5 --, (b) --L 4 --O--L 5 --, (c) --L 4 --S(O) n --L 5 -- (d) --L 4 --L 6 --C(W)--N(R 5)--L 5 --, (e) --L 4 --L 6 --S(O)m--N(R 5)--L 5 --, (f) --L 4 --N(R 5)--C(W)--L 7 --L 5 --, (g) --L 4 --N(R 5)--S(O) p --L 7 --L 5 --, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

Substitution des 1,2-Diazinsystems mit symm.Trioxanylradikalen; ein Zugang zu Pyridazincarbaldehyden. 13. Mitteilung ueber Pyridazine

Pyridazine (1) and 3-methylpyridazine (5) selectively are attacked by symm.trioxanyl radicals in positions 4 and/or 5 yielding 2, 3, 6, 7, 8, while 4-methylpyridazine (10) under similar conditions reacts to give not only C-5 substitution product 11, but also 3- and/or 6-trioxanylsubstituted methylpyridazines 12-15.The structures of the isomeric compounds were confirmed on basis of pmr-data.By hydrolysis of 6, 11, and 12 the unknown formylmethylpyridazines 9, 16 and 17 were prepared.Compound 16 was found to undergo intermolecular aldol-type addition easily yielding lactol 18.Synthesis of pyridazinecarboxaldehyde (4) starting from 1 is presented.